Xin Lang Cai Jing·2025-12-11 10:24Core Viewpoint - The company is undergoing significant changes in governance and management, aiming for high-quality development and a strategic shift towards internationalization, digitalization, and innovation, with a notable performance turnaround expected in Q3 2025 [1][2]. Governance and Management Changes - The company has completed adjustments to its executive team by 2025, with a new chairman, Li Xiaojun, who previously led a public transport group, indicating a focus on improving operational quality [2]. - The new governance structure is expected to enhance the company's operational quality, with a focus on internationalization, digitalization, and research innovation [2]. Financial Performance - In Q3 2025, the company reported a revenue of 19.771 billion yuan, reflecting a year-on-year growth of approximately 10% [2]. - The net profit attributable to shareholders for Q3 2025 was 664 million yuan, showing a year-on-year increase of about 29% [2]. Dividend Policy - The dividend payout ratio is set to increase to 46% in 2024, up from around 30% in the previous five years, with an expected dividend yield of approximately 2.81% for A shares and 4.83% for H shares [1][2]. Strategic Planning - In November 2025, the company will hold a special meeting to mobilize efforts for achieving its operational goals for the "14th Five-Year Plan" and to ensure a solid foundation for becoming a world-class enterprise during the "15th Five-Year Plan" [1][2]. - The company has initiated a comprehensive strategic planning process for the "15th Five-Year Plan" and digital transformation, aiming for long-term growth [2]. Business Segments Performance - The large commercial segment is a revenue cornerstone, with a CAGR of approximately 6% from 2020 to 2024, and a projected revenue of 54.55 billion yuan in 2024, showing a year-on-year increase of 3% [3]. - The traditional Chinese medicine segment is under pressure, with a revenue decline of 10% in 2024, while the Chinese medicine revenue grew at a CAGR of 8% during the same period [3]. - The health segment is expected to grow at a CAGR of about 5% from 2020 to 2024, with a revenue of 9.705 billion yuan in 2024, despite a year-on-year decline of 13% [3]. Revenue and Profit Forecast - The company forecasts revenues of 79.001 billion yuan, 84.061 billion yuan, and 89.45 billion yuan for 2025 to 2027, with year-on-year growth rates of approximately 5.3%, 6.4%, and 6.4% respectively [4]. - The projected net profits for the same period are 3.735 billion yuan, 3.963 billion yuan, and 4.427 billion yuan, with respective growth rates of about 31.7%, 6.1%, and 11.7% [4].